Targeting gene expression to tumor cells with loss of wild-type p53 function

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Cancer Gene Therapy

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.cgt.7700091PMID 10678350
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• p53 tumor suppressor gene therapy for cancer.

  1999cited by this paper
• Molecular epidemiology of human cancer.

  1998cited by this paper
• Strategies for achieving multiple layers of selectivity in gene therapy.

  1998cited by this paper
• P53 tumor suppressor gene therapy for cancer.

  1998cited by this paper
• In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene.

  1997cited by this paper
• Gene therapy for cancer: what have we done and where are we going?

  1997cited by this paper
• Gene therapy - promises, problems and prospects

  1997cited by this paper
• p53; from inductive signal to cellular effect.

  1997cited by this paper
• Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressor

  1997cited by this paper
• Progress in Transcriptionally Targeted and Regulatable Vectors for Genetic Therapy

  1997cited by this paper
• Abrogation of wild-type p53 mediated growth-inhibition by nuclear exclusion.

  1996cited by this paper
• TP53 tumour suppressor gene: clues to molecular carcinogenesis and cancer therapy.

  1996cited by this paper
• Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation

  1996cited by this paper
• The 1995 Walter Hubert Lecture--molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour-suppressor gene.

  1996cited by this paper
• Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage

  1996cited by this paper
• An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells

  1996cited by this paper
• p53: puzzle and paradigm.

  1996cited by this paper
• Cancer gene therapy and immunotherapy (review).

  1996cited by this paper
• Transcriptional Regulatory Sequences of Carcinoembryonic Antigen: Identification and Use with Cytosine Deaminase for Tumor-Specific Gene Therapy

  1995cited by this paper
• Tetracycline-reversible silencing of eukaryotic promoters

  1995influential reference
• Response of heat shock element within the human HSP70 promoter to mutated p53 genes.

  1995influential reference
• Small peptides activate the latent sequence-specific DNA binding function of p53.

  1995cited by this paper
• Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.

  1994cited by this paper
• Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

  1994cited by this paper
• Identification of a p53-dependent negative response element in the bcl-2 gene.

  1994cited by this paper
• Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness.

  1994cited by this paper
• Cyclin G is a transcriptional target of the p53 tumor suppressor protein.

  1994cited by this paper
• Identification of a DNA element that can enhance p53-mediated transactivation.

  1993cited by this paper
• The tumor suppressor p53.

  1993cited by this paper
• Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53

  1993cited by this paper
• Gain of function mutations in p53

  1993cited by this paper
• In vitro and in vivo targeting of gene expression to melanoma cells.

  1993cited by this paper
• Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications.

  1993cited by this paper
• WAF1, a potential mediator of p53 tumor suppression.

  1993cited by this paper
• Regulation of the human hsp70 promoter by p53.

  1993cited by this paper
• Antisense technology: biological utility and practical considerations.

  1993cited by this paper
• mdm2 expression is induced by wild type p53 activity.

  1993cited by this paper
• The tumore suppressor p53

  1993cited by this paper
• Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells

  1992cited by this paper
• Modulation of activity of the promoter of the human MDR1 gene by Ras and p53.

  1992cited by this paper
• Expression of the normal p53 gene induces differentiation of K562 cells.

  1992cited by this paper
• A transcriptionally active DNA-binding site for human p53 protein complexes

  1992cited by this paper
• Wild-type p53 binds to the TATA-binding protein and represses transcription.

  1992cited by this paper
• Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions.

  1992cited by this paper
• Regulated expression of a mammalian nonsense suppressor tRNA gene in vivo and in vitro using the lac operator/repressor system

  1992cited by this paper
• p53 function and dysfunction.

  1992cited by this paper
• Definition of a consensus binding site for p53

  1992cited by this paper
• Response of human breast cancer cells to heat shock and chemotherapeutic drugs.

  1992cited by this paper
• Progression of colorectal cancer is associated with multiple tumor suppressor gene defects but inhibition of tumorigenicity is accomplished by correction of any single defect via chromosome transfer

  1992cited by this paper
• Oncogenic forms of p53 inhibit p53-regulated gene expression.

  1992cited by this paper
• Identification of p53 as a sequence-specific DNA-binding protein

  1991cited by this paper
• Participation of p53 protein in the cellular response to DNA damage.

  1991cited by this paper
• Wild-type p53 can down-modulate the activity of various promoters.

  1991cited by this paper
• Luciferase reporter gene vectors for analysis of promoters and enhancers.

  1988cited by this paper

• Gene Therapy in Oncology

  2020cites this paper
• Comparative analysis of p53 and p21 proteins in normal cervix and HPV associated precancerous and cancerous lesions of cervix

  2015cites this paper
• Targeted gene therapy for canine osteosarcoma : preliminary investigations

  2010cites this paper
• p53-Induced Growth Arrest Is Regulated by the Mitochondrial SirT3 Deacetylase

  2010cites this paper
• Use of p53 for therapy of human cancer

  2007cites this paper
• [The use of p53 as a tool for human cancer therapy].

  2007cites this paper
• Transcription of the putative tumor suppressor gene HCCS1 requires binding of ETS-2 to its consensus near the transcription start site

  2006cites this paper
• Plasmid Engineering for Controlled and Sustained Gene Expression for Nonviral Gene Therapy

  2006cites this paper
• Effects of Polycyclic Aromatic Hydrocarbons (PAHs) on Vascular Endothelial Growth Factor Induction through Phosphatidylinositol 3-Kinase/AP-1-dependent, HIF-1α-independent Pathway*

  2006cites this paper
• Reversible inactivation of the transcriptional function of P53 protein by farnesylation

  2006cites this paper
• Cancer gene therapy

  2005cites this paper
• Expression of cyclooxygenase-2 in epithelial ovarian tumors and its relation to vascular endothelial growth factor and p53 expression

  2005cites this paper
• Are p53 inhibitors potentially useful therapeutics?

  2005cites this paper
• p53: fighting cancer.

  2004cites this paper
• Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell–based cancer vaccination

  2004cites this paper
• p53: 25 years after its discovery.

  2004cites this paper
• Viruses and Apoptosis

  2004cites this paper
• Signal transduction and apoptosis pathways as therapeutic targets.

  2004cites this paper
• The p53-Mdm2 pathway: targets for the development of new anticancer therapeutics.

  2003cites this paper
• Methods for screening tumors for p53 status and therapeutic exploitation

  2003cites this paper
• Spatial and temporal control of transgene expression in vivo using a heat‐sensitive promoter and MRI‐guided focused ultrasound

  2003cites this paper
• Prostate-specific expression of p53(R172L) differentially regulates p21, Bax, and mdm2 to inhibit prostate cancer progression and prolong survival.

  2003cites this paper
• The tumor-selective over-expression of the human Hsp 70 gene is attributed to the aberrant controls at both initiation and elongation levels of transcription

  2003influential citation
• Therapeutic exploitation of the p53 pathway.

  2002cites this paper
• Molecular characterization of colorectal neoplasia in translational research.

  2001cites this paper
• Targeting the replication of adenovirus to p53-defective thyroid carcinoma with a p53-regulated Cre/loxP system

  2001cites this paper
• Conditional gene targeting for cancer gene therapy.

  2001cites this paper
• Tumour-specific therapeutic adenovirus vectors: repression of transgene expression in healthy cells by endogenous p53

  2001cites this paper
• Exploiting the p53 pathway for cancer diagnosis and therapy.

  1999cites this paper